Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
© 2022 The Author(s)..
HCV damages the hepatocytes ending with hepatocellular carcinoma (HCC). The direct-acting antivirals (DAAs) treatment has raised hopes for reducing the incidence of HCC. However, several scientific debate regarding the impact of DAAs on the occurrence of HCC in patients with cirrhosis. We aimed to study the Cirrhosis Risk Score (CRS), several clinical factors and tumor characteristics between patients who developed HCC either with or without DAAs treatment "DAA-exposed HCC patients" and "DAA-unexposed HCC patients".
Methods: CRS was assessed via genotyping by allelic discrimination assays in HCV patients who developed de novo HCC (with DAAs (DAA-exposed HCC patients, n = 50), and without DAAs treatment (DAA-unexposed HCC patients, n = 40)). APRI, FIB-4 scores, and tumor characteristics were assessed.
Results: Around 60% and 48% of DAA-exposed HCC patients and DAA-unexposed HCC patients; respectively had high CRS scores without significant difference. DAA-exposed HCC patients showed elevated Albumin, Hemoglobin and decreased ALT, AST compared with DAA-unexposed HCC patients (P = 0.002, 0.04, <0.001 and 0.006; respectively). FIB4 and APRI didn't reach the statistical difference between the studied groups. DAA-exposed HCC patients have higher overall survival (OS) than DAA-unexposed HCC patients (median: 30 & 15 months; respectively (p = 0.019)). Moreover, no significant differences were observed between the two groups in their focal lesion characteristics.
Conclusion: All studied patients are genetically predisposed to develop HCC. Moreover, DAAs significantly improved the OS and the biochemical parameters. No differences between the two groups were detected regarding their tumor characteristics. Accordingly, the appearance of HCC after treatment is attributed to the natural course of cirrhosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Heliyon - 8(2022), 8 vom: 15. Aug., Seite e10119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dawood, Reham M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic Hepatitis C |
|---|
| Anmerkungen: |
Date Revised 30.08.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.heliyon.2022.e10119 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345506928 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345506928 | ||
| 003 | DE-627 | ||
| 005 | 20231226025217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.heliyon.2022.e10119 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345506928 | ||
| 035 | |a (NLM)36033258 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dawood, Reham M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a HCV damages the hepatocytes ending with hepatocellular carcinoma (HCC). The direct-acting antivirals (DAAs) treatment has raised hopes for reducing the incidence of HCC. However, several scientific debate regarding the impact of DAAs on the occurrence of HCC in patients with cirrhosis. We aimed to study the Cirrhosis Risk Score (CRS), several clinical factors and tumor characteristics between patients who developed HCC either with or without DAAs treatment "DAA-exposed HCC patients" and "DAA-unexposed HCC patients" | ||
| 520 | |a Methods: CRS was assessed via genotyping by allelic discrimination assays in HCV patients who developed de novo HCC (with DAAs (DAA-exposed HCC patients, n = 50), and without DAAs treatment (DAA-unexposed HCC patients, n = 40)). APRI, FIB-4 scores, and tumor characteristics were assessed | ||
| 520 | |a Results: Around 60% and 48% of DAA-exposed HCC patients and DAA-unexposed HCC patients; respectively had high CRS scores without significant difference. DAA-exposed HCC patients showed elevated Albumin, Hemoglobin and decreased ALT, AST compared with DAA-unexposed HCC patients (P = 0.002, 0.04, <0.001 and 0.006; respectively). FIB4 and APRI didn't reach the statistical difference between the studied groups. DAA-exposed HCC patients have higher overall survival (OS) than DAA-unexposed HCC patients (median: 30 & 15 months; respectively (p = 0.019)). Moreover, no significant differences were observed between the two groups in their focal lesion characteristics | ||
| 520 | |a Conclusion: All studied patients are genetically predisposed to develop HCC. Moreover, DAAs significantly improved the OS and the biochemical parameters. No differences between the two groups were detected regarding their tumor characteristics. Accordingly, the appearance of HCC after treatment is attributed to the natural course of cirrhosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic Hepatitis C | |
| 650 | 4 | |a Cirrhosis risk score | |
| 650 | 4 | |a DAA-Exposed HCC patients | |
| 650 | 4 | |a DAA-Unexposed HCC patients | |
| 650 | 4 | |a DAAs | |
| 650 | 4 | |a Genetic variants | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a Hepatocellular Carcinoma | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Tumor characteristics | |
| 700 | 1 | |a El-Meguid, Mai Abd |e verfasserin |4 aut | |
| 700 | 1 | |a Shousha, Hend Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Elsayed, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Nabeel, Mohamed Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Yosry, Ayman |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelaziz, Ashraf |e verfasserin |4 aut | |
| 700 | 1 | |a Salum, Ghada M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heliyon |d 2015 |g 8(2022), 8 vom: 15. Aug., Seite e10119 |w (DE-627)NLM255913095 |x 2405-8440 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:8 |g day:15 |g month:08 |g pages:e10119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.heliyon.2022.e10119 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 8 |b 15 |c 08 |h e10119 | ||